Peter Ceccacci
Chief Financial Officer at Lakewood-Amedex Biotherapeutics Inc. (LABT) since April 2026
Peter Ceccacci has filed 1 insider report with the SEC since May 2026, as chief Financial Officer at Lakewood-Amedex Biotherapeutics Inc. (LABT). The latest filing, on May 1, 2026, is a Form 3: Peter Ceccacci became an insider at Lakewood-Amedex Biotherapeutics Inc. (LABT).
- Filings
- 1
- Companies
- 1
- Bought on market
- None
- Sold on market
- None
Companies where Peter Ceccacci is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Financial Officersince April 2026 | 468,148 | $0.2824 | May 1, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
Other insiders at the same companies
Questions about Peter Ceccacci
- What is Peter Ceccacci's role at Lakewood-Amedex Biotherapeutics Inc.?
- Peter Ceccacci reports to the SEC as chief Financial Officer at Lakewood-Amedex Biotherapeutics Inc. (LABT), according to the latest filing on May 1, 2026.
- How many shares does Peter Ceccacci own?
- After the latest filing that states it, Peter Ceccacci directly owned 468,148 shares of Lakewood-Amedex Biotherapeutics Inc. (LABT). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Peter Ceccacci bought or sold stock recently?
- No open-market purchases or sales by Peter Ceccacci are on file.
- How do I get alerts when Peter Ceccacci files?
- Follow Peter Ceccacci on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Peter Ceccacci (SEC CIK 0002096417). Totals count each trade once, skipping amendments whose original is on file, from May 1, 2026 on. View on SEC EDGAR